CEACAM1 and fatty liver disease: In accordance with our results, earlier studies on experimental animal models reported that mice with null deletion of CEACAM1 or with liver-specific inactivation of CEACAM1 subsequently developed chronic hyperinsulinemia, insulin resistance, hepatic steatosis and visceral obesity [26–28].